Abstract
Thyroid cancer is a common malignancy derived from the endocrine system and the incidence of thyroid cancer is on the rise. Papillary thyroid carcinoma (PTC) is the most common type, and 90% of PTC patients have long-term survival, but the recurrence rate is still as high as 30%. Current diagnostic and postoperative monitoring techniques have been developed, but their negative rates and interfering factors also occupy an absolute proportion, and lack specific markers for the prognosis of PTC. Studies have shown that microRNAs (miRNAs) are associated with the development, metastasis and invasiveness of PTC and as a biomarker to aid in the diagnosis and monitoring of recurrence, and to determine the prognosis for specific markers. The future of PTC diagnosis, treatment and improve prognosis has broad prospects. This review mainly describes the development of miRNA as biomarkers for the diagnosis, recurrence and prognosis of PTC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of clinical otorhinolaryngology, head, and neck surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
